FCD-11: A First-in-Class COMPASS Inhibitor in Cancer Therapeutics
Zhao, Z.; Karunanidhi, M.; Gold, S.; St John, L.; Liaqat, R.; Iwanaszko, M.; Bigas, C.; Uchida, E.; Mineji, K.; Watanabe, J.; Aznar-Benitah, S.; Hashizume, R.; Mishra, R.; Shilatifard, A.
Show abstract
COMPASS (Complex of proteins associated with Set1) are highly conserved chromatin regulatory complexes responsible for all methylation marks on histone H3 lysine 4 (H3K4). The COMPASS protein SET1A is upregulated in metastatic breast cancer, and its H3K4 methyltransferase activity promotes metastasis in a palmitic acid diet setting. We identify and characterize FCD-11, a first-in-class small molecule inhibitor of COMPASS activity designed to disrupt the termolecular interface between COMPASS SET domains, ASH2L, and RBBP5. FCD-11 significantly inhibited the H3K4me3 methyltransferase activity of SET1A/COMPASS and MLL1/COMPASS in vitro. ChIP-seq and CETSA indicated that FCD-11 selectively inhibits SET1A/COMPASS activity in mouse embryonic stem cells and breast cancer cell lines. FCD-11 significantly reduced tumor size and extended survival in mouse models of breast cancer. Our findings establish FCD-11 as a potent, COMPASS-specific inhibitor lead compound with preclinical efficacy in breast cancer models and therapeutic potential for cancers with abnormal dependence on SET1A/COMPASS activity.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cancer-associated DNA Hypermethylation of Polycomb Targets Requires DNMT3A Dual Recognition of Histone H2AK119 Ubiquitination and the Nucleosome Acidic Patch 96%
- Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities 95%
- Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving calcium-calcineurin-NFAT signaling 95%
Similar papers in this journal
Similar papers in this journal
- SETD2 suppresses tumorigenesis in a KRASG12C-driven lung cancer model and its catalytic activity is regulated by histone acetylation 96%
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 96%
- SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species 95%
Similar papers in this journal
- Structural basis of the regulation of normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2 95%
- Identification of RNF114 as ADPr-Ub reader through non-hydrolysable ubiquitinated ADP-ribose 95%
- Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.